Nouvelles promesses de l'immunothérapie pour les carcinomes épidermoïdes de la tête et du cou: entre rationnel scientifique et efficacité clinique

info:eu-repo/semantics/publishe

Thérapies biologiques ciblées et cancer thyroïdien récidivant: Enfin un standard thérapeutique ?

info:eu-repo/semantics/publishe

Cytotoxic drug extravasations in cancer patients: Diagnosis, prevention and management

Chemotherapy remains a cornerstone for the treatment of cancer, either for solid and haematological malignancies, in early and advanced stage disease. The very great majority of cytotoxic drugs are administered by intravenous perfusions. Moreover, various toxicities are associated to anticancer chemotherapy, depending on the type of cytotoxic agent considered. Such acute or delayed toxicities are currently well managed, allowing a preservation of patient's quality of life during the scheduled treatment. However, cytotoxic drug extravasation can be considered as an iatrogenic complication well described in the literature, but also probably underestimated and understudied, with a clear lack of general consensus for the medical management, even if practical rules are being developed in clinical institutions. © 2012 by Nova Science Publishers, Inc. All rights reserved.Chapter 14SCOPUS: ch.binfo:eu-repo/semantics/publishe

Molecular markers, molecular-targeted therapies and taxanes: how to integrate the progress into clinical research and practice for the management of head and neck cancers.

EditorialReviewSCOPUS: ed.jinfo:eu-repo/semantics/publishe

Recurrent thyroid cancer: a molecular-based therapeutic breakthrough.

Thyroid cancer is a group of heterogeneous rare malignancies, with an increasing incidence. Management of recurrent thyroid cancer not amenable to local therapy such as surgery, radiotherapy or radio-iodine ablation remains very challenging. Indeed, chemotherapy allows a very limited impact on the outcomes of this cancer.Journal ArticleReviewSCOPUS: re.jinfo:eu-repo/semantics/publishe

Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: An overview about well-established and recently emerging clinical data

Despite the overwhelming evidence for the role of granulocyte colony stimulating factors (G-CSF) in managing febrile neutropenia (FN) risk, chemotherapy-induced neutropenia (CIN) and/or FN still remain the most common reasons for reducing relative dose intensity (RDI) and/or delaying chemotherapy schedule. The need to maintain RDI to ensure optimal clinical outcomes is one of the key rationales for utilizing G-CSF. There is a high incidence of reduced RDI in both curative and palliative settings, and this observation is especially evidenced in retrospective analyses. Reduced RDI leads to significantly decreased survival outcomes and quality of life in various malignancies at various clinical settings and stages. Beyond its role as a surrogate prognostic marker, high-grade CIN may have an unexpected predictive role in clinical practice, as illustrated by several data relating CIN occurrence with favorable survival outcomes; this may be due to the fact that body surface area (BSA) – based calculation of dose may not fully account for the pharmacokinetics (PK) of cytotoxic drugs and the fact that there may be variability in drug metabolism between patients treated with same chemotherapy regimens.SCOPUS: re.jinfo:eu-repo/semantics/publishe

Carcinome adénoïde kystique du nasopharynx, une entité clinique rare en quête d'innovations thérapeutiques : cas clinique et revue de la littérature

Nasopharyngeal adenoid cystic carcinoma is a rare tumour. Compared with others nasopharyngeal tumours, it is characterised by slow evolution but it is locally aggressive and has a high tendency to recurrences. Due to the rarity of cases, no consensus exists about treatment approaches. We report the case of 45-year-old-man with a locally advanced adenoid cystic carcinoma. The patient received concurrent chemoradiation and had a good objective response. After one year, he developed a paucisymptomatic lung metastasis. The follow-up showed local recurrence after 3 years. One cycle of chemotherapy was given but poorly supported. Carbon ion radiotherapy was proposed. The aim of this work is to review the literature concerning this rare malignancy and discusses treatment approaches in initial situations and during recurrences.SCOPUS: ar.jinfo:eu-repo/semantics/publishe

Salivary gland carcinomas, paranasal sinus cancers and melanoma of the head and neck: an update about rare but challenging tumors.

PURPOSE OF REVIEW: This is a review about recent clinical developments in rare cancers of the head and neck. RECENT FINDINGS: Progress in molecular biology techniques has allowed the identification of new prognostic factors, and potential molecular-targeted therapies. This is of importance since chemotherapy continues to play a role but is still limited in this group of malignancies. New techniques of irradiation such as intensity-modulated radiotherapy and three-dimensional conformal radiotherapy appear to improve the locoregional control of these tumors. Surgery continues to be the cornerstone of treatment, with a growing interest in the technique of sentinel lymph node biopsy. SUMMARY: As salivary gland carcinomas, paranasal sinus cancers and melanoma of the head and neck are rare malignancies, these tumors must be treated in specialized anticancer centers with access to the latest surgical and irradiation techniques. Moreover, clinical studies with translational research are needed to identify strong prognostic and predictive factors, and effective molecular-targeted therapies.Journal ArticleReviewinfo:eu-repo/semantics/publishe

Unusual presentation of nasopharyngeal carcinoma with rectal metastasis.

Nasopharyngeal carcinoma (NPC) is a rare tumour that mainly metastasizes in lymph nodes, bones, lungs and liver. Colorectal metastases of NPC are extremely rare phenomenon and associated with a poor prognosis. We reported here a case of NPC with rectal metastasis, we discussed the treatment modalities and the prognosis after reviewing the similar cases described in the literature.info:eu-repo/semantics/publishe

Clinical trial design in head and neck cancer: From past experiences to future perspectives

info:eu-repo/semantics/publishe